Food Companies Reshape Products as GLP-1 Drug Use Grows
Weight-loss medications like Ozempic are curbing appetites and cutting consumer spending on food, pushing businesses to adapt.
The rapid adoption of GLP-1 medications such as Ozempic and Wegovy is sending ripple effects far beyond the doctor's office, forcing food manufacturers, retailers and apparel companies to rethink core assumptions about how Americans eat, shop and dress.
Consumers taking the drugs are eating less, opting for smaller portion sizes and spending less on groceries overall. That behavioral shift is registering in corporate earnings reports and prompting executives across the food industry to weigh reformulations, packaging changes and new product lines aimed at buyers with diminished appetites.
Read more Howard Buffett to Succeed Warren as Berkshire Hathaway Chairman →
The clothing sector is also feeling the impact. Shoppers losing significant weight are trading down to smaller sizes, a trend that is altering demand patterns for apparel brands and retailers who must now account for a shifting customer base.
The GLP-1 phenomenon presents a strategic dilemma for the food industry in particular. Companies that sell high-calorie, high-volume products face potential long-term revenue pressure if a meaningful share of their customer base sustains medically assisted weight loss. Some firms are already exploring nutrient-dense, protein-forward options designed to appeal to users who eat less but want more nutritional value per bite.
Analysts warn the adjustment period could prove uneven, with some categories — snacks, sugary beverages, large-format packaging — more exposed than others. How quickly and how broadly GLP-1 adoption scales will likely determine the pace at which businesses must move. Continue reading at NYT > Business.
